RESUMEN
BACKGROUND: ChatGPT® (OpenAI; California, USA) is an open-access chatbot developed using artificial intelligence (AI) that generates human-like responses. OBJECTIVE: To evaluate the ChatGPT-4's concordance with three dermatologic surgeons on reconstructions for dermatological surgical defects. METHODS: A total of 70 cases of non-melanoma skin cancer treated with surgery were obtained from clinical records for analysis. A list of 30 reconstruction options was designed by the main authors which included primary closure, secondary skin closure, skin flaps and skin grafts. Three blinded dermatologic surgeons, along with ChatGPT-4, were asked to select two reconstruction options from the list. RESULTS: Seventy responses were analyzed using Cohen's kappa looking for concordance between each dermatologist and ChatGPT. The level of agreement among dermatologic surgeons was higher compared to that between dermatologic surgeons and ChatGPT, highlighting differences in decision-making. In the best reconstruction technique, the results indicated a fair level of agreement among the dermatologists ranging between κ 0.268 and 0.331. However, the concordance with ChatGPT-4 and the dermatologists was slight with κ values from 0.107 to 0.121. In the analysis of the second-choice options, the dermatologists showed slight agreement. In contrast, the level of concordance between ChatGPT-4 and the dermatologists was below chance. CONCLUSIONS: As anticipated, this study reveals variability in medical decisions between dermatologic surgeons and ChatGPT. Although these tools offer exciting possibilities for the future, it's vital to acknowledge the risk of inadvertently rely on non-certified AI for medical advice.
RESUMEN
Pemphigus foliaceus (PF) is an autoimmune blistering disorder which affects the superficial layers of the epidermis with rare mucosal involvement. We present the case of a 12-year-old girl with PF involving the eyes and eyelids. A literature review of pediatric nonendemic PF revealed another two cases with ocular manifestations. Eyelid involvement is an uncommon feature of PF that should be properly identified and treated.
RESUMEN
Antiphospholipid syndrome (APS) is an acquired thrombophilic disorder in which autoantibodies are produced against a variety of phospholipids and phospholipid-binding proteins. The purpose of this article is to review cutaneous findings in patients with APS diagnosis. An overview regarding prevalence, description, pathogenesis and histopathology, are described for cutaneous manifestations of APS.
Asunto(s)
Anticuerpos Antifosfolípidos/inmunología , Síndrome Antifosfolípido/patología , Livedo Reticularis/patología , Enfermedades de la Piel/patología , Vasculitis/patología , Adulto , Anciano , Anetodermia/etiología , Anetodermia/patología , Anticuerpos Anticardiolipina/inmunología , Síndrome Antifosfolípido/diagnóstico , Síndrome Antifosfolípido/epidemiología , Síndrome Antifosfolípido/inmunología , Biopsia , Femenino , Gangrena/etiología , Gangrena/patología , Humanos , Livedo Reticularis/diagnóstico , Livedo Reticularis/etiología , Livedo Reticularis/inmunología , Inhibidor de Coagulación del Lupus/inmunología , Masculino , Papulosis Atrófica Maligna/etiología , Papulosis Atrófica Maligna/patología , Persona de Mediana Edad , Necrosis/diagnóstico , Necrosis/etiología , Prevalencia , Enfermedades de la Piel/inmunología , Úlcera/patología , Vasculitis/etiologíaAsunto(s)
Carcinoma Basocelular , Neoplasias de los Labios , Neoplasias Cutáneas , Humanos , Labio/patología , Carcinoma Basocelular/cirugía , Carcinoma Basocelular/patología , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/cirugía , Neoplasias Cutáneas/patología , Membrana Mucosa/patología , Neoplasias de los Labios/cirugía , Neoplasias de los Labios/patología , Mucosa Bucal/patologíaAsunto(s)
Adiposis Dolorosa , Herida Quirúrgica , Adiposis Dolorosa/diagnóstico , Adiposis Dolorosa/cirugía , Humanos , DolorRESUMEN
BACKGROUND: Wound healing is a complex process; during the process angiogenesis takes place, that presents clinically as erythema, telangiectasia and edema. Pulsed dye laser (PDL) has a wavelength of 585-595 nm, which targets the chromophore hemoglobin. OBJECTIVE: Determine the level of improvement of post-dermatological surgery scars. METHODS: Thirty patients attending for excision lesion were recruited. They were randomized to 1 of 2 groups. Group 1 scar was randomly divided into 2 parts, one half received PDL 595 nm on 3 occasions; the first after suture removal, 15 and 45 days. Group 2 in one half laser application was simulated while the other was left untreated. The Vancouver scar scale (VSS) was used by an external evaluator to assess the scars. Two skin biopsies were also obtained one before and one after laser treatment. RESULTS: The VSS at 45 days decreased in a significant way in the treatment group from 4 to 1 (P = .005). In the control group decreased from 2 to 1.3 (P = .056). No significant difference was found between the presence of inflammatory infiltrate of patients in the placebo group. CONCLUSION: This study confirmed the usefulness of pulsed dye laser for improving the appearance of scars.
Asunto(s)
Cicatriz/radioterapia , Procedimientos Quirúrgicos Dermatologicos/efectos adversos , Láseres de Colorantes/uso terapéutico , Complicaciones Posoperatorias/radioterapia , Cicatriz/etiología , Cicatriz/patología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/patología , Método Simple Ciego , Resultado del Tratamiento , Cicatrización de HeridasAsunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Alopecia Areata/terapia , Ciclobutanos/uso terapéutico , Ciclopropanos/uso terapéutico , Inmunoterapia , Adolescente , Adulto , Niño , Preescolar , Femenino , Hospitales Universitarios , Humanos , Masculino , México , Persona de Mediana Edad , Estudios Retrospectivos , Adulto JovenAsunto(s)
Vendajes de Compresión , Oído Externo/patología , Queloide/patología , Queloide/terapia , Esteroides/administración & dosificación , Adolescente , Adulto , Terapia Combinada , Oído Externo/cirugía , Femenino , Humanos , Inyecciones Intralesiones , Queloide/tratamiento farmacológico , Queloide/cirugía , Masculino , Recurrencia , Esteroides/uso terapéutico , Adulto JovenRESUMEN
BACKGROUND: Abdominal Cesarean sections (C-sections) are frequently associated with an increased risk of excessive or unpleasant scarring. A topical scar gel containing extract of Allium cepae, allantoin and heparin (Contractubex®; Merz Pharmaceuticals GmbH, Germany), has shown efficacy in improving the appearance of various scar types. OBJECTIVE: To investigate the efficacy of the topical scar gel, Contractubex, in the early treatment of C-section scars. MATERIALS & METHODS: A total of 61 females, aged ≥18 years, who had given birth by elective C-section for the first time within the last 5-10 days, were included in this prospective, randomized, single-center study. Patients were advised to apply the topical scar gel twice daily (treatment group), or received no treatment (control group). Efficacy was evaluated at 6 and 12 weeks after a baseline visit using the Patient and Observer Scar Assessment Scale (POSAS), a validated scar assessment tool comprised of a Patient Scale and an Observer Scale. RESULTS: Analysis revealed a significant change in the POSAS Patient Scale total score, with a 14.2% improvement in the treatment group compared with a decline of similar magnitude (-14.8%) in the control group at week 6. Significant improvements were also seen for POSAS Patient Scale sub-items in the treatment group compared with the control group for scar color (13.6% vs -18.5%, respectively, P=0.0284), stiffness (12.5% vs -34.6%, respectively, P=0.0029), and irregularity (29.4% vs -46.2%, respectively, P=0.0140) after 6 weeks of treatment. No significant changes were observed for the POSAS Observer Scale total score or its subitems after treatment with the topical scar gel, although there was a strong overall trend in favor of the treatment group. No significant adverse events were observed during the study. CONCLUSION: Contractubex represents an efficacious and well-tolerated preventative treatment that rapidly and significantly improves the color, stiffness and irregularity of C-section scars.
Asunto(s)
Alantoína/uso terapéutico , Cesárea/efectos adversos , Cicatriz/prevención & control , Heparina/uso terapéutico , Extractos Vegetales/uso terapéutico , Administración Cutánea , Adolescente , Adulto , Alantoína/administración & dosificación , Cicatriz/etiología , Combinación de Medicamentos , Femenino , Geles , Heparina/administración & dosificación , Humanos , Extractos Vegetales/administración & dosificación , Embarazo , Estudios Prospectivos , Resultado del Tratamiento , Adulto JovenAsunto(s)
Cejas/efectos de la radiación , Terapia por Luz de Baja Intensidad/efectos adversos , Equipos de Seguridad , Traumatismos por Radiación/prevención & control , Quemaduras/prevención & control , Técnicas Cosméticas/efectos adversos , Diseño de Equipo , Femenino , Humanos , Terapia por Luz de Baja Intensidad/métodos , Masculino , Prevención Primaria/instrumentación , Equipos de Seguridad/estadística & datos numéricos , Sensibilidad y EspecificidadRESUMEN
BACKGROUND: Melasma is an acquired pigmentation disorder with a complex multifactorial etiopathogenesis. Oral tranexamic acid (TA) is a promising drug for its treatment and may enhance outcomes when used in combination. OBJECTIVE: To provide evidence of the efficacy and safety of oral TA as a monotherapy, and in combination with a triple combination cream, for treating melasma in the Hispanic population. METHODS: Forty-four female Hispanic patients with melasma were randomly assigned to receive 325 mg of oral TA every 12 h plus f-TCC (fluocinolone-based triple combination cream) every 24 h (group A) or 325 mg of oral TA every 12 h (group B) for 8 weeks, after which both groups were crossed-over, and treated for an additional 8 weeks. Evaluations of the mMASI score, the melanin index, and the MelasQoL were made at baseline and Weeks 4, 8, 12, and 16. RESULTS: There was a 50.04% and 65.45% improvement in mMASI at Weeks 4 and 8, respectively, in group A, compared to baseline, while for Week 16, an improvement of 76.85% was achieved in group B compared to baseline. Highest scores were consistent with the use of the combined treatment modality in both groups, and were evidenced by the values of the melanin index obtained. There was no significant difference in MelasQoL scores between the 2 groups. No serious side effects were observed. CONCLUSION: The combination of oral TA and f-TCC is more effective than oral TA alone in the treatment of severe melasma in Hispanic patients.
Asunto(s)
Melanosis , Ácido Tranexámico , Terapia Combinada , Emolientes/uso terapéutico , Femenino , Humanos , Melaninas , Melanosis/tratamiento farmacológico , Resultado del TratamientoAsunto(s)
Dermoscopía/métodos , Ectima Contagioso/diagnóstico , Virus del Orf/aislamiento & purificación , Crianza de Animales Domésticos , Animales , Biopsia con Aguja , Ectima Contagioso/patología , Ectima Contagioso/terapia , Dedos , Humanos , Inmunohistoquímica , Persona de Mediana Edad , Exposición Profesional/efectos adversos , Enfermedades Raras , Ovinos , Zoonosis/diagnóstico , Zoonosis/terapiaRESUMEN
BACKGROUND: Dermabrasion is a surgical procedure that has been used for repigmentation; however, autologous transplantation of uncultured melanocytes in a suspension combined with the use of adjunct treatment provides better results. PURPOSE: To evaluate the clinical effectiveness of dermoabrasion (DA) and melanocyte-keratinocyte cell suspension transplantation (DA+MKT) vs. dermabrasion with no adjunct treatment. MATERIALS AND METHODS: We selected 11 patients (six women and five men) with stable vitiligo. From these, two achromic maculae of similar size were selected. One macule was treated with DA+MKT and the other with DA only. The main parameter of treatment efficacy was the percentage of repigmentation in the area treated, three and 12 months after implantation. RESULTS: In seven of the 11 patients, slightly better pigmentation occurred with DA+MKT. Two of these patients had a repigmentation greater than 50 percent and in two other patients, the result was similar for both techniques, although slightly better with MKT. Two more patients showed less than 20 percent repigmentation, but only in the area treated with DA+MKT. One patient showed pigmentation initially after DA+MKT only, and subsequent depigmentation. CONCLUSION: DA+MKT produced slightly better repigmentation than DA only when given without adjunct treatment in a 12-month follow-up period.
Asunto(s)
Dermabrasión/métodos , Queratinocitos/trasplante , Melanocitos/trasplante , Vitíligo/terapia , Adulto , Terapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Pigmentación de la Piel , Resultado del TratamientoRESUMEN
Vitiligo is a multifactorial disease characterized by the loss of skin pigment, which results in achromic macules and patches. There are currently several medical treatments available, which aim to arrest progression and induce skin repigmentation. These treatments alone or combined have exhibited varying degrees of pigmentation, and the majority are safe and effective. All therapies for vitiligo are limited, and no known treatment can consistently produce repigmentation in all patients. Individualized treatment is appropriate according to the location, clinical presentation and the presence of disease activity. The present review summarizes the medical treatments available for vitiligo: Systemic and topic pharmacological therapies, physical and depigmentation treatments. Several treatments are still underway and have not yet been approved. However, due to the promising preliminary results, these are also mentioned in the present review.